Up­start can­cer biotech re­cruits a top Pfiz­er on­col­o­gy re­searcher as CSO — could an IPO be far be­hind?

As Vi­vid­ion ex­ecs proud­ly showed off an $82 mil­lion B round last spring, the start­up was ea­ger to dis­cuss 3 pre­clin­i­cal pro­grams —an adap­tor pro­tein, a tran­scrip­tion fac­tor and an E3 lig­ase — that were an­gling to­ward proof-of-con­cept da­ta. Now they have found a high-pro­file ear­ly-stage phar­ma ex­ec to guide them to the promised land of clin­i­cal de­vel­op­ment.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER